首页> 美国卫生研究院文献>Neuro-Oncology >Impaired health-related quality of life in meningioma patients—a systematic review
【2h】

Impaired health-related quality of life in meningioma patients—a systematic review

机译:脑膜瘤患者健康相关生活质量受损的系统评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

While surgical and radiotherapeutic improvements increased life expectancy of meningioma patients, little is known about these patients’ health-related quality of life (HRQoL). Therefore, the objectives of this systematic review were to assess HRQoL in meningioma patients, the methodological quality of the used questionnaires (COSMIN criteria), and the reporting level of patient-reported outcomes (PROs) in the included studies (International Society of Quality of Life Research criteria).Nineteen articles met our inclusion criteria. HRQoL was measured with 13 different questionnaires, 3 validated in meningioma patients. According to our predefined cutoff, HRQoL data were reported sufficiently in 5 out of 19 studies. Both findings hamper interpretation of the PRO results.In general, meningioma patients reported clinically worse HRQoL than healthy controls. Although meningioma patients had better HRQoL than glioma patients, this difference was not clinically relevant. Radiotherapy seemed to improve some domains of HRQoL in the short term, while HRQoL decreased to pre-radiotherapy levels in the long term. Tumor resection increased HRQoL, but long-term follow-up showed persistent reduced HRQoL compared with healthy controls. These results suggest an impaired HRQoL in meningioma patients, even years after anti-tumor treatment. Results of this systematic review warrant high quality prospective studies, better instruments to assess HRQoL, and improved level of reporting for this group of patients.
机译:尽管外科手术和放射治疗的改善可以提高脑膜瘤患者的预期寿命,但对这些患者健康相关的生活质量(HRQoL)知之甚少。因此,本系统评价的目的是评估纳入研究中的脑膜瘤患者的HRQoL,所使用问卷的方法学质量(COSMIN标准)以及患者报告结果的报告水平(国际质量学会生命研究标准)。有19篇文章符合我们的纳入标准。 HRQoL用13种不同的问卷进行了测量,其中3种在脑膜瘤患者中得到了验证。根据我们预先定义的临界值,在19项研究中有5项报告了足够的HRQoL数据。这两个发现都妨碍了PRO结果的解释。总的来说,脑膜瘤患者报告的HRQoL在临床上比健康对照者差。尽管脑膜瘤患者的HRQoL比神经胶质瘤患者好,但这种差异在临床上并不相关。放射治疗似乎在短期内改善了HRQoL的某些领域,而HRQoL从长期来看已降至放射治疗前的水平。肿瘤切除增加了HRQoL,但长期随访显示与健康对照相比,HRQoL持续降低。这些结果表明,即使在抗肿瘤治疗后数年,脑膜瘤患者的HRQoL也受损。该系统评价的结果值得进行高质量的前瞻性研究,更好的评估HRQoL的手段,并提高该组患者的报告水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号